Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    P09 - Health Services Research/Health Economics - Real World Outcomes

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Health Services Research/Health Economics
    • +

      P09.53 - Comparative Effectiveness of Crizotinib versus Entrectinib in ROS1+ Non-Small Cell Lung Cancer (NSCLC) using Clinical Trial and Real-World Data

      00:00 - 00:00  |  Presenter: Laura Iadeluca

      • Abstract

      Loading...

    • +

      P09.56 - Real-World Outcomes Among Patients with ROS1-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

      00:00 - 00:00  |  Presenter: Lauren Bartolome

      • Abstract

      Loading...

  • +

    MA08 - Advances in Biomarkers for Immune Checkpoint Blockade and Targeted Therapy in Non Small Cell Lung Carcinoma

    • 16:45 - 17:45
    • 1/30/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Pathology, Molecular Pathology and Diagnostic Biomarkers
    • +

      MA08.08 - Implementation of Diagnostic Biomarker Testing in Lung Cancer: Real-World Data in Japan

      17:10 - 17:15  |  Presenter: Yasushi Yatabe

      • Abstract

      Loading...

  • +

    MA11 - Expanding Targetable Genetic Alterations in NSCLC

    • 14:15 - 15:15
    • 1/31/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Targeted Therapy - Clinically Focused
    • +

      MA11.08 - Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC

      14:40 - 14:45  |  Presenter: Julien Mazieres

      • Abstract

      Loading...